April 23, 2014

Dow Jones/VentureWire

Gynesonics Names Christopher Owens President, CEO

Gynesonics Inc., which is developing minimally invasive treatments for symptomatic uterine fibroids, has named veteran medical device executive Christopher M. Owens as president and chief executive.

Mr. Owens was most recently president and CEO at IDEV Technologies , which was acquired by Abbott Laboratoriesfor $310 million in 2013. Prior to IDEV, Mr. Owens was vice president of worldwide marketing for MicroVention, which was purchased by Terumo Corp . Before that he was VP, global research and development for the surgical division of Bausch & Lomb .

Redwood City, Calif.-based Gynesonics has developed a system for the transcervical treatment of symptomatic uterine fibroids under intrauterine ultrasound guidance. The system, VizAblate, has received CE Mark approval for commercial sale in the European Union . VizAblate is not available for sale in the U.S.

In February 2013, the company raised a $21 million Series D round from new investor HBM Partners. Other investors include Correlation Ventures , Abingworth, Advanced Technology Ventures and InterWest Partners . At the time it had raised roughly $65 million from investors altogether.

http://www.gynesonics.com

(c) 2014 Dow Jones & Company, Inc.